-
Clin Cancer Res: The efficacy and safety of the new anti-PD-L1 antibody LY3300054 for the treatment of advanced solid tumors
Time of Update: 2021-02-11
A Phase Ia/Ib PACT study (NCT02791334) evaluated a new PD-L1 inhibitor LY3300054 as a monotherapy or in combination with Remolu monoantigen, Abemaciclib, or Merestinib (a type II MET kinase inhibitor) to treat the safety, pharmacodynamics, pharmacological and anti-tumor activity of late-stage refractic solid tumors.
-
JCO: ORR for first-line treatment of patients with renal transparent cell carcinoma in the advance stage of Paboli pearl monotherapy up to 36.4%
Time of Update: 2021-02-11
Despite the inherent limitations of single-arm design, the results of this study show that Pabliju monotherapy has convincing anti-tumor activity, safe and long-lasting, for patients with advanced ccRCC (including all IMDC risk groups) and all patients with IMDC risk.
-
Cell Death Differ: PARP1, MRE11, and RAD51 together affect DNA replication stress and silky division of colorectal cancer tumor stem cells
Time of Update: 2021-02-11
in CRC-SC cells, PARP1 expression increases and regulates the rate of DNA replication in general, the study develops treatments to eliminate CRC-SCs resistance and helps clarify the potential mechanisms of RSR in CSCs.
-
The man, who has five types of cancer and doctors predict he will live up to two years, has survived for 26 years
Time of Update: 2021-02-10
At the age of 48, Jiang Yu hard (analyte), who lives in the village of Mapu in Chaonan Leiling Township, stood alone outside the hospital clinic with a diagnosis of kidney cancer, his mind echoing wit
-
Eur Radiol: Perhaps understanding the natural process of lung sub-solid nods can more accurately diagnose lung nods!
Time of Update: 2021-02-10
Most previous studies have been exploring the histological type and immersion of SSN, but no studies have been conducted to evaluate the growth rate of SSN and the natural processes of IAC.
the first 70 months of follow-up, the cumulative growth rate of IAC was significantly higher than that of non-IAC.
-
Are tumors the same thing as cancer? The doctor made it clear to you in two ways at once
Time of Update: 2021-02-10
damage to the body is relatively small, unless born in an important area so that the compression of tissue organs, and benign tumors will only grow up will not spread, most will not cause serious complications, cause patient death and so on.
-
Clin Cancer Res:ctDNA testing is a guide to treatment options for patients with metastatic colorectal cancer
Time of Update: 2021-02-10
The super-selectivity of the flanks and molecules of primary tumors helps to screen patients who are most likely to benefit from EGFR inhibition, such as left side tumors and those without rare genetic variants associated with primary resistance (HER2/MET amplification, gene fusion, PIK3CA mutations, and microsatellite instability (MSI).
-
Accelerated assessment of Cilta-cel for CAR-T therapy Citacabtagene Autoleucel to treat multiple myeloma
Time of Update: 2021-02-10
Cilta-cel is a CAR-T therapy targeted at BCMA.
Cilta-cel is being developed to treat patients with relapsed multiple myeloma (MM).
CAR-T therapy is a highly personalized technology that reprograms the patient's own T-cells to treat cancer.
-
Lancet oncol: Phased distribution and time changes in the incidence of breast and cervical cancer in many countries in 2008-17
Time of Update: 2021-02-10
Researchers collected data on the incidence of breast and cervical cancer from 2008 to 2017 from official statistics from Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, the Republic of Moldova, the Russian Federation, Ukraine and Uzbekistan, and classified them by tumor, lymph nodes, metastasis (TNM) stage and the age of available population-based cancer registration data.
-
BMC Medicine: The 3.5 million people queue study showed that BMI and waist circumference were associated with multiple cancer risks
Time of Update: 2021-02-10
As a result, Martina Recalde et al., using a forward-looking queue based on electronic health records in Catalonia, Spain, included 3,658,417 adults aged ≥18 years of age and without cancer between 2006 and 2017, investigating the association between BMI and 26 cancer risks, taking into account nonlinear relationships.
-
Cell Death Differ:PGC7 promotes cancer-causing differentiation of tumors by reshaping dna methylation patterns of key developmental transcription factors
Time of Update: 2021-02-10
previous studies have shown that the prognosis of HCC, which expresses bi-energy hepatocytocyte markers such as CK7 or CK19, is very poor, which also indicates that the mechanism of regulating the reversal of tumor cell linee is particularly important in the process of malignant transformation of HCC.
-
JAMA Surg: Warm chemotherapy in the abdominal cavity can improve the survival rate of patients with peritina false mucus tumor after surgery
Time of Update: 2021-02-10
study, for patients with peritina false mucus tumor, intracellular thermothermal chemotherapy after tumor cell reduction surgery can significantly improve the survival rate of patients.
-
Lancet Haematol: The MATRix-RICE program is effective in treating secondary CNS-soaked diffuse large B-cell lymphoma in a joint self-bodies HSCT
Time of Update: 2021-02-10
treatment with MATRix-RICE, 49 patients (65 percent; 95 percent CI 54-76) received objective remission, of which 29 (39 percent) were fully relieved.
at the end of the programme, 46 patients (61 per cent; 95 per cent CI 51-71) received objective remission with a medium duration of 26 months (IQR 16-37).
-
Clin Cancer Res: Durvalumab-Tremelimumab-radiotherapy is used to mismatch the efficacy of repairing normal metastatic colorectal cancer
Time of Update: 2021-02-10
, however, the researchers observed a rare systemic immune enhancement and subsidion (an abnormal reaction) in non-radioactive lesions.
a combined treatment of MMR-P mCRC patients with Durvalumab and Tremlimumab-RT is feasible and safe and controllable.
-
2020 World Lung Cancer Congress: LDCT screening is effective in detecting non-smoking lung cancer patients
Time of Update: 2021-02-10
, LDCT screening is particularly meaningful for detecting lung cancer patients who are at high risk and who never smoke, given the increasing incidence of lung cancer in non-smokers worldwide.
-
FDA announces: The world's 4th CAR-T cell therapy has been approved for market, treatment of recurring or refractic large B-cell lymphoma, more safe!
Time of Update: 2021-02-10
Used to treat adult patients with recurring or incurable large B-cell lymphoma (R/R LBCL), including diffuse large B-cell lymphoma (DLBCL), who did not respond to at least 2 other systemic treatments or relapsed after treatment.
Breyanzi was the first RMAT-certified regenerative medicine treatment to receive FDA approval.
-
A healthy lifestyle can increase life for more than 6 years, and non-smoking has the greatest survival benefits
Time of Update: 2021-02-10
Source: myparla.com more and more people are suffering from more than one disease because of some wrong lifestyle. figures from Scotland show that about 65 per cent of over-65s have multiple illnesse
-
World Lung Cancer Congress 2020: Keytruda combined chemotherapy doubles the survival of advanced NSCLC
Time of Update: 2021-02-10
Recently, at the 2020 World Lung Cancer Congress (WCLC) held by the International Lung Cancer Research Association (IASLC), the KEYNOTE-189 trial published the latest four-year follow-up results: In first-line treatment, combined chemotherapy with the K drug doubles the survival of patients with advanced NSCLC and provides sustained survival benefits.
-
CD73 antibody Ulliledlimab has made progress in several clinical trials in China and the United States in treating tumors
Time of Update: 2021-02-10
I-Mab, a clinical biopharmaceutical company dedicated to the discovery and development of new biologics, announced today that its proprietary CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has made progress in several clinical trials in China and the United States.
Uliledlimab is a humanized anti-CD73 antibody that effectively regulates the tumor micro-environment by inhibiting adenosine.
-
70% of cancer patients die from cancer recurrence! Why does cancer relapse?
Time of Update: 2021-02-10
some tumors grow in sensitive areas of the patient, surgery can not be completely removed, so even a little tumor, after the accumulation of time, will relapse again.
